Radioimmunodetection of prostatic cancer with 125I-labelled antibody against prostatic specific antigen.
A murine monoclonal antibody directed against human prostatic specific antigen was labelled with 125I and used in immunoscintigraphy studies of nude mice bearing xenografts of a human prostatic carcinoma cell line (DU-145). The antibody was injected intraperitoneally and the distribution was followed daily with the use of a gamma scintillation camera. Specific uptake was seen in the tumor, with optimal imaging 7-9 days after the injection of the radio-labelled antibody. Fab fragments of the radio labelled antibody were also investigated. These exhibited a strikingly shorter bio-distribution time, with optimal visualization of the tumor after 14-28 hours. Normal murine IgG and Fab fragments used in control experiments exhibited radioactivity that was comparable to that of normal tissue.
Larson
A
A
Department of Urology, University Hospital, Uppsala, Sweden.
Arnberg
H
H
Maripuu
E
E
Nilsson
S
S
D000818:Animals; D000911:Antibodies, Monoclonal; D000951:Antigens, Neoplasm / Q000276:immunology*; D006801:Humans; D007457:Iodine Radioisotopes; D008297:Male; D051379:Mice; D008819:Mice, Nude; D009368:Neoplasm Transplantation; D017430:Prostate-Specific Antigen; D011471:Prostatic Neoplasms / Q000000981:diagnostic imaging*; D011877:Radionuclide Imaging
D000911:Antibodies, Monoclonal; D000951:Antigens, Neoplasm; D007457:Iodine Radioisotopes; D017430:Prostate-Specific Antigen